Communiqués Alembic Limited NSE India S.E.

Actions

ALEMBICLTD

INE426A01027

Développement et opérations immobilières

Marché Fermé - NSE India S.E. 13:53:29 07/09/2026			Varia. 5j.	Varia. 1 janv.
108,05 ^INR	-3,02%		+8,01%	+6,78%

11/08	Alembic Limited publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
19/05	Alembic Limited recommande le versement d'un dividende au titre de l'exercice clos le 31 mars 2026	CI

Communiqués

04/07/25	Alembic : Annual Report 2024-25	PU
27/05/25	Supreme Court Rules Against Ex-Post Facto Environment Clearance	AQ
14/08/24	Alembic Pharmaceuticals announces USFDA Dabigatran Etexilate Capsules, 110 mg	AQ
25/07/24	Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg	AQ
07/08/23	Alembic Pharmaceuticals - Revenue up 18% to Rs. 1486 crores in Q-1 FY24	AQ
12/07/23	Alembic : Annual Report 2022-23	PU
12/05/23	Alembic : AL-Extract-Consolidated Financial Result-IE-Eng-12.05.2023	PU
12/05/23	Alembic : AL-Extract-Consolidated Financial Result-FE-Guj-12.05.2023	PU
12/05/23	Alembic : Audited Financial Results for the Quarter and Financial year ended 31st March, 2023	PU
14/11/22	Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules 25 mg and 50 mg	AQ
02/11/22	Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility Final Approval for Glycopyrrolate Injection USP	AQ
28/10/22	Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP, 30 mg/5 mL, 100 mg/16.7 mL, and 300 mg/50 mL Multiple-Dose Vials.	AQ
04/10/22	Alembic : Spurt in Volume	PU
16/09/22	TTAB Trifusal: ALEMBIC PHARMACEUTICALS Refusals Affirmed - Likelihood Of Confusion, Failure-to-Function, And Nonuse	AQ
30/08/22	Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg.	AQ
09/08/22	Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%	AQ
05/08/22	Alembic reports revenue for Q1 FY23 Rs. 1262 Cr.	AQ
01/08/22	Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Diclofenac Sodium Topical Gel, 3%	AQ
25/05/22	Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg a~d 801 mg	AQ
08/04/22	Alembic Pharmaceuticals announces USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg	AQ
07/09/21	Alembic : Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Metronidazole Gel USP. 1%	AQ
12/07/21	Alembic : Pharmaceuticals announces USFOA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg.	AQ
09/07/21	Alembic : Pharmaceuticals announces USFDA Final Approval for Desipramine Hydrochloride Tablets USP, 10 mg. 25 mg. 50 mg, 75 mg, 100 mg, and 150 mg	AQ
05/05/21	Alembic : Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Tentative Approval for Metronidazole Gel USP, 1%.	AQ
15/02/21	Alembic : Pharmaceuticals announces its wholly-owned subsidiary, Alembic Global Holding SA receives USFDA Final Approval for Treprostinil Injection	AQ